Bisphosphonates and cardiac electrophysiology: should the red flag be raised higher?
Bisphosphonates and cardiac electrophysiology: should the red flag be raised higher?
复制标题
双磷酸盐和心脏电生理学:是否应该提高危险信号?
DOI:
10.1111/jce.12349
复制
发表时间:
2014
影响因子:
2.7
通讯作者:
Avula,UmaMaheshR
中科院分区:
文献类型:
--
作者:
Kalifa,Jérôme;Avula,UmaMaheshR
Bisphosphonates are widely employed to decrease bone loss in disorders characterized by increased osteoclast-mediated bone resorption, such as senile osteoporosis. 1 While generally well tolerated, side effects such as an acute inflammatory phase reaction, osteonecrosis of the jaw, gastro-intestinal disorders or hypocalcemia have been described. 1 Also, contradictory reports of an association between atrial fibrillation (AF) and the use bisphosphonates has led to confusing statements and sent mixed messages to practitioners and patients. 2 Details on these conflicting observations are summarized in previously published review articles. 1-3 Interestingly, several hypotheses linking bisphosphonates to the onset of AF have been formulated: an acute increase in pro-inflammatory cytokines, disturbances in calcium homeostasis or extra-cellular matrix remodeling. 2 To date, however, none of these premises have been tested, the mechanisms by which bisphosphonates may impact cardiac electrophysiology are unknown, and as of late 2008, the Food and Drug Administration failed to identify a clear association and concluded that no change in prescribing practices was warranted. 1, 2In this issue of the Journal of Cardiovascular Electrophysiology, Bonilla et al. present a multi-faceted investigation describing plausible mechanisms for bisphosphonates-induced cardiac arrhythmias. Their results have substantial mechanistic depth and, albeit provocative, put at question the previous status quo on an association between bisphosphonates and cardiac arrhythmias.